Retrospective Review of Outcomes in Non-Invasive Mucinous Appendiceal Neoplasms with and without Peritoneal Spread: A Cohort Study

• Published in: Current oncology (Toronto) 2022-11, Vol.29 (12), p.9125-9134
• Main Authors: Sipok, Arkadii, Dort, Jonathan M, Visioni, Anthony, Bijelic, Lana
• Format: Article
• Language: English
• Subjects: Adenocarcinoma, Mucinous - surgery; Appendiceal Neoplasms - therapy; Appendix; Cancer; Care and treatment; Chemotherapy; Cohort Studies; Comparative analysis; cytoreductive surgery; heated intraperitoneal chemotherapy; Humans; Medical research; Medicine, Experimental; mucinous carcinoma peritonei; Percutaneous Coronary Intervention; peritoneal metastases; Peritoneal Neoplasms - therapy; pseudomyxoma peritonei; Retrospective Studies; Tumors
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol29120714

Patients treated surgically for local non-invasive mucinous appendiceal neoplasm (NI-MAN) may recur with the development of peritoneal dissemination (PD). The risk of recurrence and predictive factors are not well studied. Patients with NI-MAN, with or without peritoneal dissemination at presentation, were included. Patients with limited disease underwent surgical resection only. Patients with peritoneal dissemination underwent cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Patients without PD (nPD) were compared to those who presented with PD. Thirty-nine patients were included, 25 in nPD and 14 in PD. LAMN was diagnosed in 96% and 93% of patients in nPD and PD, respectively. Acellular mucin on the peritoneal surface was seen in 16% of nPD patients vs. 50% of PD patients ( = 0.019). Two (8%) patients in the nPD group who had LAMN without wall rupture recurred, at 57 and 68 months, with a PCI of 9 and 22. The recurrence rate in the PD group was 36%. All recurred patients underwent CRS+HIPEC. A peritoneal recurrence is possible in NI-MANs confined to the appendix even with an intact wall at initial diagnosis. The peritoneal disease may occur with significant delay, which is longer than a conventional follow-up.